Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
about
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Hepatic lipid accumulation alters global histone h3 lysine 9 and 4 trimethylation in the peroxisome proliferator-activated receptor alpha network.Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.Concurrent activation of liver X receptor and peroxisome proliferator-activated receptor alpha exacerbates hepatic steatosis in high fat diet-induced obese mice.LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).SteatoNet: the first integrated human metabolic model with multi-layered regulation to investigate liver-associated pathologies.NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications.Bilirubin Binding to PPARα Inhibits Lipid Accumulation.Evaluation of Methionine Content in a High-Fat and Choline-Deficient Diet on Body Weight Gain and the Development of Non-Alcoholic Steatohepatitis in Mice.PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.Polyphenol-Rich Fraction of Ecklonia cava Improves Nonalcoholic Fatty Liver Disease in High Fat Diet-Fed Mice.Nordihydroguaiaretic acid improves metabolic dysregulation and aberrant hepatic lipid metabolism in mice by both PPARα-dependent and -independent pathways.Characterization of WY 14,643 and its Complex with Aldose Reductase.Activation of PPARα by Wy-14643 ameliorates systemic lipopolysaccharide-induced acute lung injury.Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.Proteome Characteristics of Non-Alcoholic Steatohepatitis Liver Tissue and Associated Hepatocellular Carcinomas.Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.Pirinixic acids: flexible fatty acid mimetics with various biological activities.Perfluoroalkyl acids-induced liver steatosis: Effects on genes controlling lipid homeostasis.The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.Therapeutic applications of the versatile fatty acid mimetic WY14643.Effects of sleeve gastrectomy on lipid metabolism in an obese diabetic rat model.Strain dependence of diet-induced NASH and liver fibrosis in obese mice is linked to diabetes and inflammatory phenotype.Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis.Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.Editor's Highlight: Mechanistic Toxicity Tests Based on an Adverse Outcome Pathway Network for Hepatic Steatosis.The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.Tongxinluo attenuates reperfusion injury in diabetic hearts by angiopoietin-like 4-mediated protection of endothelial barrier integrity via PPAR-α pathway.
P2860
Q30241952-2A3ABC12-F7B2-472D-BEAE-746B2F7A770AQ34413666-7A5880A2-E245-4F35-A3D0-BB31C192CEABQ34647400-EE4B15AF-9BCB-47FD-A1C6-458760C8969FQ34770055-D70EA946-7CDB-487B-B3BD-8B72E6EFDF98Q35415945-5DE6F23C-FE51-4463-A6FA-2184719ABC5AQ35513572-F43EA38A-B1DE-4127-897C-4F17013C5D30Q35931190-F8DD255A-C619-49D0-96BD-9C71558C8756Q35987425-A30CA712-72D9-4878-AA7F-2E3293B731FFQ36159376-B42E65EB-E5B0-4335-9066-E1AC5CF258E2Q36253614-0ECFA37B-2049-4835-A617-F5C0464F8270Q36329720-A0538158-D2F3-4359-B96E-1A8DF146BB99Q36527942-D4DE95ED-27EB-4C5C-9AC9-9D324C814C26Q37323900-0669970A-07F1-4C04-989A-2D5A30890CD7Q37407237-8653A97A-8FC4-4A52-970F-589BE06E8C94Q37640263-492A619B-3897-406E-B70F-C91FC69350C7Q37691021-B3C7ED9D-D5B5-4395-A71E-6E1CD437EE44Q38121574-2585B5BA-EAEF-47B1-B3FF-303F684074E8Q38574980-70821599-777A-4999-B113-688B1F99D891Q38723141-09739471-1402-406E-895E-BA0A81238950Q38752520-96C854FC-4654-4C93-BAED-06BC0470E6A8Q39038230-37CE6908-9B3D-45D6-B523-5DDA73196F37Q44207649-5C0A1EB9-B091-4955-B434-8AD6B7216272Q44675090-CBE8D9D6-7435-43BF-AD2E-263D7A042E16Q45031991-4B7F33BC-8FB6-4DC0-AC30-C80BA1BFBA17Q45345979-C33353C9-7F42-40AE-B69D-77BF5C08BD01Q47807772-1F9E74E3-CE15-41BE-8099-E00F697CCF9FQ52699074-495A22C8-C0D8-422E-BFFC-9F12AEE56CBAQ55285122-6D273CCD-6201-49AC-8CF6-DB0B4F5874A4
P2860
Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Peroxisome proliferator-activa ...... non-alcoholic steatohepatitis.
@en
Peroxisome proliferator-activa ...... non-alcoholic steatohepatitis.
@nl
type
label
Peroxisome proliferator-activa ...... non-alcoholic steatohepatitis.
@en
Peroxisome proliferator-activa ...... non-alcoholic steatohepatitis.
@nl
prefLabel
Peroxisome proliferator-activa ...... non-alcoholic steatohepatitis.
@en
Peroxisome proliferator-activa ...... non-alcoholic steatohepatitis.
@nl
P2093
P2860
P1476
Peroxisome proliferator-activa ...... non-alcoholic steatohepatitis.
@en
P2093
Claire Z Larter
Derrick M Van Rooyen
Geoffrey C Farrell
John Brooling
Kamaljit Ghatora
Matthew M Yeh
P2860
P304
P356
10.1111/J.1440-1746.2011.06939.X
P577
2012-02-01T00:00:00Z